BBO-11818, an orally bioavailable, highly potent and non-covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRAS-mutant preclinical models

BBO-11818, an orally bioavailable, highly potent and non covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRASG12D and KRASG12V preclinical models